INOVIO PHARMACEUTICALS, INC. (INO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -79.26M USD | Operating Income (Loss) |
| Revenue | 0.00 USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 48.49M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-79.26M | $0.00 | (m) | $48.49M | (m) | (m) |
| 2026-03-31 | $-83.72M | $0.00 | (m) | $52.19M | (m) | (m) |
| 2025-12-31 | $-86.82M | $65.34K | (m) | $54.21M | (m) | -132871.32% |
| 2025-09-30 | $-89.72M | $182.34K | (m) | $56.83M | (m) | -49202.88% |
| 2025-06-30 | $-95.85M | $182.34K | (m) | $62.23M | (m) | -52568.64% |
| 2025-03-31 | $-105.96M | $283.10K | (m) | $70.80M | (m) | -37430.19% |
| 2024-12-31 | $-112.40M | $217.76K | (m) | $75.62M | (m) | -51616.91% |
| 2024-09-30 | $-119.42M | $203.41K | (m) | $79.99M | (m) | -58709.67% |
| 2024-06-30 | $-127.63M | $591.86K | (m) | $76.76M | (m) | -21564.06% |
| 2024-03-31 | $-131.47M | $717.07K | (m) | $77.41M | (m) | -18334.80% |
| 2023-12-31 | $-143.94M | $832.01K | (m) | $86.68M | (m) | -17300.28% |
| 2023-09-30 | $-172.49M | $854.02K | (m) | $111.54M | (m) | -20197.59% |
| 2023-06-30 | $-172.70M | $9.62M | (m) | $129.13M | (m) | -1795.24% |
| 2023-03-31 | $-239.79M | $10.18M | (m) | $161.85M | (m) | -2355.96% |
| 2022-12-31 | $-267.57M | $10.26M | (m) | $187.65M | (m) | -2607.35% |
| 2022-09-30 | $-317.14M | $10.98M | (m) | $237.83M | (m) | -2889.17% |
| 2022-06-30 | $-341.33M | $2.11M | (m) | $251.83M | (m) | -16144.10% |
| 2022-03-31 | $-320.40M | $1.60M | (m) | $266.17M | (m) | -19990.89% |
| 2021-12-31 | $-301.22M | $1.77M | (m) | $249.24M | (m) | -16972.34% |
| 2021-09-30 | $-225.05M | $6.52M | (m) | $183.24M | (m) | -3453.67% |
| 2021-06-30 | $-201.43M | $6.46M | (m) | $162.61M | (m) | -3117.70% |
| 2021-03-31 | $-151.40M | $6.46M | (m) | $114.18M | (m) | -2345.51% |
| 2020-12-31 | $-124.08M | $7.41M | (m) | $94.25M | (m) | -1674.25% |
| 2020-09-30 | $-125.16M | $2.11M | (m) | $89.95M | (m) | -5931.57% |
| 2020-06-30 | $-112.79M | $2.74M | (m) | $82.63M | (m) | -4115.06% |
| 2020-03-31 | $-107.81M | $2.61M | (m) | $82.74M | (m) | -4131.60% |
| 2019-12-31 | $-111.11M | $4.11M | (m) | $88.02M | (m) | -2702.10% |
| 2019-09-30 | $-110.19M | $6.34M | (m) | $92.38M | (m) | -1739.31% |
| 2019-06-30 | $-112.88M | $7.47M | (m) | $95.09M | (m) | -1511.27% |
| 2019-03-31 | $-89.88M | $31.78M | (m) | $95.07M | (m) | -282.80% |
| 2018-12-31 | $-94.09M | $30.48M | (m) | $95.26M | (m) | -308.68% |
| 2018-09-30 | $-87.48M | $36.77M | (m) | $93.53M | (m) | -237.93% |
| 2018-06-30 | $-90.02M | $37.41M | (m) | $97.19M | (m) | -240.64% |
| 2018-03-31 | $-94.46M | $33.37M | (m) | $98.61M | (m) | -283.02% |
| 2017-12-31 | $-83.64M | $42.22M | (m) | $98.57M | (m) | -198.11% |
| 2017-09-30 | $-83.12M | $41.95M | (m) | $97.84M | (m) | -198.15% |
| 2017-06-30 | $-74.13M | $51.84M | (m) | $99.31M | (m) | -142.99% |
| 2017-03-31 | $-82.72M | $37.63M | (m) | $95.07M | (m) | -219.80% |
| 2016-12-31 | $-76.24M | $35.37M | (m) | $88.71M | (m) | -215.55% |
| 2016-09-30 | $-68.40M | $32.79M | (m) | $80.40M | (m) | -208.60% |
| 2016-06-30 | $-44.47M | $44.43M | (m) | $69.50M | (m) | -100.09% |
| 2016-03-31 | $-41.37M | $43.52M | (m) | $66.55M | (m) | -95.06% |
| 2015-12-31 | $-34.28M | $40.57M | (m) | $57.79M | (m) | -84.50% |
| 2015-09-30 | $-30.77M | $37.09M | (m) | $51.43M | (m) | -82.95% |
| 2015-06-30 | $-42.83M | $14.75M | (m) | $42.38M | (m) | -290.36% |
| 2015-03-31 | $-37.86M | $13.27M | (m) | $35.30M | (m) | -285.42% |
| 2014-12-31 | $-39.50M | $10.46M | (m) | $34.10M | (m) | -377.71% |
| 2014-09-30 | $-36.49M | $9.74M | (m) | $31.25M | (m) | -374.65% |
| 2014-06-30 | $-27.39M | $17.39M | (m) | $29.68M | (m) | -157.55% |
| 2014-03-31 | $-22.91M | $14.37M | (m) | $24.48M | (m) | -159.43% |
| 2013-12-31 | $-19.54M | $13.47M | (m) | $21.37M | (m) | -145.12% |
| 2013-09-30 | $-17.77M | $12.86M | (m) | $19.41M | (m) | -138.14% |
| 2013-06-30 | $-24.83M | $4.23M | (m) | $18.94M | (m) | -586.84% |
| 2013-03-31 | $-25.94M | $3.88M | (m) | $19.06M | (m) | -668.45% |
| 2012-12-31 | $-23.49M | $4.12M | (m) | $17.98M | (m) | -570.42% |
| 2012-09-30 | $-23.05M | $4.62M | (m) | $17.70M | (m) | -499.21% |
| 2012-06-30 | $-23.09M | $6.40M | (m) | $19.72M | (m) | -360.82% |
| 2012-03-31 | $-21.44M | $8.38M | (m) | $19.65M | (m) | -255.74% |
| 2011-12-31 | $-21.64M | $9.80M | (m) | $20.03M | (m) | -220.91% |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $-19.22M | $6.14M | (m) | $13.26M | (m) | -312.79% |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $-13.96M | $9.12M | (m) | $9.41M | (m) | -153.04% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |